Evaluating the cost-effectiveness of combination antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Uganda
Andreas Kuznik, Mohammed Lamorde, Sabine Hermans, Barbara Castelnuovo, Brandon Auerbach, Aggrey Semeere, Joseph Sempa, Mark Ssennono, Fred Ssewankambo & Yukari C Manabe
Volume 90, Number 8, August 2012, 595-603
Table 2. Results from four models used to evaluate the incremental cost-effectiveness of combination antiretroviral therapy (ART) in Uganda relative to other treatment regimens or none, 2011
| Variable | Model |
||||||
|---|---|---|---|---|---|---|---|
| 1a: 18-month ART, relative to |
1b: lifetime ART, relative to |
2a: 18-month ART, relative to NT | 2b: lifetime ART, relative to NT | ||||
| sdNVP | DT | sdNVP | DT | ||||
| Cost difference per patient (US$) | 482 | 467 | 4817 | 4747 | 689 | 6883 | |
| Cost offset per patient (US$) | 240 | 148 | 884 | 547 | 395 | 1455 | |
| Incremental cost per patient (US$)a | 242 | 318 | 3933 | 4200 | 294 | 5428 | |
| DALYs averted per patient | 5.21 | 3.22 | 19.20 | 11.87 | 8.58 | 31.60 | |
| Incremental cost per DALY averted (US$) | 46 | 99 | 205 | 354 | 34 | 172 | |
DALY, disability-adjusted life year; DT, dual therapy; NT, no treatment; sdNVP, single-dose nevirapine; US$, United States dollar.
a Calculated by subtracting the cost offset from the cost difference.